Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma
Radiation Oncology Journal
;
: 289-294, 2017.
Artigo
em Inglês
| WPRIM
| ID: wpr-144709
ABSTRACT
Sorafenib is widely used for unresectable and metastatic hepatocellular carcinomas. Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin that occurs after the administration of certain drugs. RRD after sorafenib treatment is rare; five cases have been reported thus far. We describe a 44-year-old man irradiated for chest wall bone metastasis from hepatocellular carcinoma. Eight days after radiotherapy completion, systemic therapy for metastatic hepatocellular carcinoma was initiated with sorafenib treatment. Eleven days after starting sorafenib, the patient complained of erythematous rash with pruritus in the chest wall, in a location consistent with the previous radiation field. Sorafenib was continued at the same dose, despite the RRD. The skin reaction subsided over the next 2 weeks without any medical intervention.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prurido
/
Radiodermite
/
Radioterapia
/
Pele
/
Carcinoma Hepatocelular
/
Parede Torácica
/
Exantema
/
Metástase Neoplásica
Limite:
Adulto
/
Humanos
Idioma:
Inglês
Revista:
Radiation Oncology Journal
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS